The NHC is an independent statutory body charged with prioritising new and existing health technologies and making recommendations to the Minister of Health.

The New Zealand Government has asked that all new diagnostic and treatment (non-pharmaceutical) services, and significant expansions of existing services, are to be referred to the NHC.

The Committee also provides advice on what technologies are obsolete or no longer providing value for money for New Zealanders.

Latest news

  • 30 June 2015

    Consultation on the Tier 2 AMD assessment was undertaken in March and April 2015.  The Committee considered the submissions at its May meeting.  Consideration of the valuable feedback from stakeholders has resulted in further more detailed Tier 3 analysis being undertaken for four components of the end to end model of care for AMD.  These include further analysis on the use of anti-VEGF agents as well as population screening, low vision rehabilitation and genomic diagnostic risk stratification.

  • 13 April 2015

    A referral for assessment of Intraoperative Radiotherapy (IORT) interventions available for breast cancer was put forward as part of the 2013/14 referral round.  This resulted in a Tier 2 assessment to explore the uses of IORT, which cancer types are highest priorities for further assessment and

  • 13 April 2015

    Age-related macular degeneration (AMD) is the leading cause of blindness in New Zealand in those aged over 50, accounting for half of all cases.